Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

$1.08

DILUTED ADJUSTED INCOME PER COMMON

SHARE $1.18 $0.92

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING 68,118 66,931

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING-ASSUMING DILUTION 78,920 79,030

Notes to Reconciliation of GAAP Net Income to Adjusted Net Income

(1) To exclude the on-going amortization of acquired intangible assets ($24.0 million in 2008; $22.3 million in 2007), accelerated depreciation related to the CIMA LABS restructuring ($1.6 million in 2008), accelerated depreciation related to the proposed divestiture at the Mitry-Mory facility ($2.9 million in 2008), and the write-off of purchase commitments in excess of estimated requirements ($26.0 million in 2008).

(2) In 2008, to exclude accelerated depreciation related to the proposed divestiture at the Mitry-Mory facility. In 2007, to exclude the recognition of a milestone related to the FDA's acceptance of our NDA filing for TREANDA (bendamustine HCl).

(3) To exclude charges related to the estimated termination payments due to Takeda Pharmaceuticals North America, Inc.

(4) In 2008, to exclude charges related to the settlement of investigations by the Offices of the Attorney General of Connecticut and Massachusetts and estimated relator attorney fees. In 2007, to exclude the reserve established for the minimum liability related to the potential settlement of the investigations by the U.S. Attorney's Office.

(5) To exclude the forgiveness of a mortgage loan by the Pennsylvania Industrial Development Board ("PIDA").

(6) To exclude the accrued interest related to the settlement reached with the U.S. Attorney's Office.

(7) To exclude costs related to the CIMA LABS restructuring announced in January 2008.

(8) To reflect the tax effect of pre-tax adjustments at the applicable tax rates and certain other
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... The report “Service Quality Management and Telco Customer ... - Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” defines ... forecasting of revenues. , Browse 152 market data ... TOC on “Service Quality Management (SQM) and Telco Customer ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 PlasmaTech ... care in critical areas, announced the closing of an underwritten ... to purchase up to an aggregate 3,500,000 shares of common ... $.01 per warrant.  The warrants have a per share exercise ...
(Date:12/24/2014)... 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... clinical grade hypothermic storage and cryopreservation freeze ... cells and tissues  ("BioLife" or the "Company"), today announced that ... May 4, 2015 (the "Annual Meeting"). Because the ...
(Date:12/24/2014)... 23, 2014 GMO corn cases filed across ... in the process of being consolidated in a Kansas federal ... Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 in ... Management of the Syngenta GMO corn multidistrict litigation (MDL) has ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... most popular among makers of ... EVANSTON, Ill., Sept. 30 The ... by global sales and marketing,consulting firm ZS ... number of companies - in pharmaceutical/biotech, medical,products ...
... (Nasdaq: VRNM ), a pioneer in the ... announced today,that Janet Roemer, Executive Vice President and ... upcoming William Blair & Company 2008,Small-Cap Growth Stock ... a.m. ET on Tuesday, October 7, 2008 and ...
... Genomic,Health, Inc. (Nasdaq: GHDX ) today announced ... Officer, will present at the JMP,Securities Healthcare Focus ... at 10:00 a.m. ET., To access the ... the Investor Relations section of Genomic Health,s,website at ...
Cached Biology Technology:Quota-Based Compensation Plans Outpace Ranking Plans 2Quota-Based Compensation Plans Outpace Ranking Plans 3Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference 2Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference 3
(Date:1/22/2015)... 2015 Infinisource has launched its new NXG series of ... G2 sets a higher standard for collecting attendance and labor ... With plug-and-play installation, touch screen interface and seamless connection to ... time collection solution for the small to mid-size employer. ...
(Date:12/22/2014)... , Dec. 22, 2014  The 2014 Holiday Season ... as Acuity Market Intelligence reports that the long anticipated ... forecasts that intensifying demand for smart phones, tablets, and ... global market of 2.5 billion users with nearly 4.8 ...
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ...
Breaking Biology News(10 mins):Infinisource's NXG series sets new time clock standard 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... led by the Karolinska Institutet, Sweden and the University of ... and the composition of human gastrointestinal bacteria. In a study ... the team outline new evidence suggesting that the human genome ... billions of microbes in the human gastrointestinal tract collectively known ...
... senior author Morris J. Birnbaum, MD, PhD, the Willard ... for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, ... works in a different way than previously understood. Their ... hormone glucagon,s ability to generate an important signaling molecule, ...
... cells in all higher organisms cells need to bind to ... tissues. Mysteries have remained, however, about exactly how cells manage ... Scripps Research Institute (TSRI) have now solved part of this ... α-catenin, which is essential to this process. The ...
Cached Biology News:International study suggests human genes influence gut microbial composition 2Most-used diabetes drug works in different way than previously thought 2New study defines the long-sought structure of a protein necessary for cell-cell interaction 2
Rabbit polyclonal antibody to Neuromedin U Receptor 1 (GPR66)...
... in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and ... royalties for your hard work and endeavour! ... build it up,and market it internationally. We ...
... is causing shortages in your laboratory or ... cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us ... up,and market it internationally. We work under ...
...
Biology Products: